General Information of Drug (ID: DMZV6YT)

Drug Name
US8569313, Inhibitor 14 Drug Info
Synonyms SCHEMBL8197672; SCHEMBL19309547; CHEMBL3655685; US8569313, Inhibitor 14; BDBM104906
Cross-matching ID
PubChem CID
59603780
TTD Drug ID
DMZV6YT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US8569313, Inhibitor 18 DMXTCGM N. A. N. A. Patented [1]
US8569313, Inhibitor 19 DMLXG43 N. A. N. A. Patented [1]
US8569313, Inhibitor 15 DMTMG02 N. A. N. A. Patented [1]
PMID23849879C3 DMUW3MT Discovery agent N.A. Investigative [2]
PMID25489658C4d DMWZJT0 Discovery agent N.A. Investigative [3]
Benzamidine DM37GWL Discovery agent N.A. Investigative [4]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine DMFXKN1 Discovery agent N.A. Investigative [5]
Inhibitor 1 [Colombo et al., 2012] DMUQHMP Discovery agent N.A. Investigative [6]
3-tapap DMKSUV9 Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Suppressor of tumorigenicity 14 protein (ST14) TTPRO7W ST14_HUMAN Inhibitor [1]

References

1 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313.
2 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51.
3 Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418).